Johnson & Johnson

4Q Revenues: $18.4 billion (+5%)

4Q Earnings: $3.5 billion (+37%)

FY Revenues: $71.3 billion (+6%)

FY Earnings: $13.8 billion (+27%)

Comments: Pharmaceutical sales were $7.3 billion in the quarter, up 12%, and $28.1 billion for the year, up 11%. Domestic sales increased 7% in the quarter and 12% for the year. International sales increased 2% in the quarter and 10% for the year. Sales growth was driven by REMICADE and SIMPONI, STELARA, INVEGA SUSTENNA/XEPLION, PREZISTA, DOXIL/CAELYX, and VELCADE, as well as newer products ZYTIGA for metastatic, castration-resistant prostate cancer, XARELTO, an oral anticoagulant, the combined sales of COMPLERA/EVIPLERA, EDURANT for HIV, and INVOKANA for type 2 diabetes. Sales were negatively impacted by loss of exclusivity for ACIPHEX/ PARIET, and CONCERTA. Worldwide Consumer sales were $14.7 billion for the year, up 2%. Worldwide Medical Devices and Diagnostics sales were $28.5 billion, up 4%.